JPWO2021161105A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021161105A5 JPWO2021161105A5 JP2022548875A JP2022548875A JPWO2021161105A5 JP WO2021161105 A5 JPWO2021161105 A5 JP WO2021161105A5 JP 2022548875 A JP2022548875 A JP 2022548875A JP 2022548875 A JP2022548875 A JP 2022548875A JP WO2021161105 A5 JPWO2021161105 A5 JP WO2021161105A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977008P | 2020-02-14 | 2020-02-14 | |
| US62/977,008 | 2020-02-14 | ||
| PCT/IB2021/000091 WO2021161105A1 (en) | 2020-02-14 | 2021-02-12 | P2x3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513373A JP2023513373A (ja) | 2023-03-30 |
| JPWO2021161105A5 true JPWO2021161105A5 (https=) | 2024-02-20 |
| JP2023513373A5 JP2023513373A5 (https=) | 2024-02-20 |
Family
ID=77292083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548875A Ceased JP2023513373A (ja) | 2020-02-14 | 2021-02-12 | Ｐ２ｘ３修飾薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312557A1 (https=) |
| EP (1) | EP4103564A4 (https=) |
| JP (1) | JP2023513373A (https=) |
| KR (1) | KR20220141331A (https=) |
| CN (2) | CN119039290A (https=) |
| AU (1) | AU2021219097A1 (https=) |
| BR (1) | BR112022015858A2 (https=) |
| CA (1) | CA3170664A1 (https=) |
| IL (1) | IL295393A (https=) |
| MX (1) | MX2022009762A (https=) |
| WO (1) | WO2021161105A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| EP4103572A4 (en) * | 2020-02-14 | 2024-03-06 | Bellus Health Cough Inc. | MAKING A P2X3 ANTAGONIST |
| WO2021244634A1 (zh) * | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| CN114805340A (zh) * | 2021-01-22 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN116635389A (zh) * | 2021-01-29 | 2023-08-22 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| CN115043836B (zh) * | 2021-08-20 | 2023-07-18 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012011518B8 (pt) * | 2009-11-18 | 2023-01-10 | Astrazeneca Ab | Compostos, composição farmacêutica, kit e usos de um composto |
| US9598409B2 (en) * | 2013-01-31 | 2017-03-21 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CA3115939A1 (en) * | 2018-10-10 | 2020-04-16 | Bellus Health Cough Inc. | Treatment of pruritus with p2x3 antagonists |
| WO2020135771A1 (zh) * | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
| AU2020228760A1 (en) * | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
-
2021
- 2021-02-12 JP JP2022548875A patent/JP2023513373A/ja not_active Ceased
- 2021-02-12 BR BR112022015858A patent/BR112022015858A2/pt not_active IP Right Cessation
- 2021-02-12 WO PCT/IB2021/000091 patent/WO2021161105A1/en not_active Ceased
- 2021-02-12 MX MX2022009762A patent/MX2022009762A/es unknown
- 2021-02-12 EP EP21754440.2A patent/EP4103564A4/en active Pending
- 2021-02-12 CN CN202411099037.4A patent/CN119039290A/zh active Pending
- 2021-02-12 IL IL295393A patent/IL295393A/en unknown
- 2021-02-12 KR KR1020227031507A patent/KR20220141331A/ko active Pending
- 2021-02-12 US US17/929,035 patent/US20230312557A1/en active Pending
- 2021-02-12 CN CN202180028882.0A patent/CN115413279A/zh active Pending
- 2021-02-12 AU AU2021219097A patent/AU2021219097A1/en not_active Abandoned
- 2021-02-12 CA CA3170664A patent/CA3170664A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504899A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2019504898A5 (https=) | ||
| JP2005509024A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2014500322A5 (https=) | ||
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| RU2009127855A (ru) | 4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций | |
| JP2007512299A5 (https=) | ||
| JPWO2022177917A5 (https=) | ||
| JPWO2022251502A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| JP2022137237A5 (https=) | ||
| JP2010527984A5 (https=) | ||
| JP2020519582A (ja) | 新規なピペリジン−２，６−ジオン誘導体及びその用途 | |
| JPWO2021161105A5 (https=) | ||
| JP2010527985A5 (https=) | ||
| RU2010136721A (ru) | Агонисты мускариновых рецепторов, композиции, способы лечения ими и способы их изготовления | |
| JPWO2022212489A5 (https=) | ||
| JP2024112835A5 (https=) | ||
| JPWO2022067094A5 (https=) | ||
| JPWO2020033520A5 (https=) | ||
| JPWO2020117635A5 (https=) | ||
| JPWO2020176757A5 (https=) | ||
| JPWO2023072257A5 (https=) |